Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Table 1

Patient characteristics.

Male/female	19/18
Age (years)	Median 22 (range 15–55)
15–17	5
18–39	27
>40	5
Race
Asian	4
Black	1
White	25
Unknown	7
Osteosarcoma subtype
Chondroblastic	9
Fibroblastic	3
Osteoblastic	21
Telangiectatic	4
Number of recurrences
1	19
2	8
3+	10
Number of lung nodules
1	21
2	8
3+	8